Individual Differences of Drug Efficacy and Toxicity in Patients With Coronary Artery Disease

Clinical Value and Omics Study of The Individual Differences in Medication Responses in Patients With Coronary Heart Disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061570

Enrollment

Unknown

Registered

2022-06-29

Start date

2022-06-15

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

Divide into groups according to outcomes:Observational study, no Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with coronary heart disease aged 18-80 years.

Exclusion criteria

Exclusion criteria: 1. Renal insufficiency (defined as serum creatinine concentration > 2 times the upper limit of normal [230 umol/L], renal transplantation or dialysis); 2. Hepatic insufficiency (defined as serum transaminase concentration > 2 times the upper limit of normal [80 U/L], or a diagnosis of cirrhosis); 3. Pre-existing bleeding disorders; 4. Deing pregnant or lactating; 5. Advanced cancer or hemodialysis; 6. History of thyroid problems, and use of antithyroid drugs or thyroid hormone medication; 7. Incomplete information about cardiovascular events during follow-up.

Design outcomes

Primary

Measure	Time frame
MACE (Major Adverse Cardiovascular Events);	—

Secondary

Measure	Time frame
Bleeding;Statin-induced myopathy (SIM);Contrast-induced acute kidney injury, CI-AKI;	—

Countries

China

Contacts

Public ContactHanzohra Upur

Sun Yat-Sen University

wupuer@mail2.sysu.edu.cn+86 13199911128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026